The DOI matches its Crossref record, with a small difference in title or year; 50 of the 51 references it cites were found in a registry or an index.
Efficacy and Safety of Intranasal Esketamine Adjunctive to Oral Antidepressant Therapy in Treatment-Resistant Depression: A Randomized Clinical Trial
Open accessAbstract
Importance: Approximately one-third of patients with major depressive disorder (MDD) do not respond to available antidepressants. Objective: To assess the efficacy, safety, and dose-response of intranasal esketamine hydrochloride in patients with treatment-resistant depression (TRD). Design, Setting, and Participants: This phase 2, double-blind, doubly randomized, delayed-start, placebo-controlled study was conducted in multiple outpatient referral centers from January 28, 2014, to September 25, 2015. The study consisted of 4 phases: (1) screening, (2) double-blind treatment (days 1-15), composed of two 1-week periods, (3) optional open-label treatment (days 15-74), and (4) posttreatment follow-up (8 weeks). One hundred twenty-six adults with a DSM-IV-TR diagnosis of MDD and history of inadequate response to 2 or more antidepressants (ie, TRD) were screened, 67 were randomized, and 60 completed both double-blind periods. Intent-to-treat analysis was used in evaluation of the findings. Interventions: In period 1, participants were randomized (3:1:1:1) to placebo (n = 33), esketamine 28 mg (n = 11), 56 mg (n = 11), or 84 mg (n = 12) twice weekly. In period 2, 28 placebo-treated participants with moderate-to-severe symptoms were rerandomized (1:1:1:1) to 1 of the 4 treatment arms; those with mild symptoms continued receiving placebo. Participants continued their existing antidepressant treatment during the study. During the open-label phase, dosing frequency was reduced from twice weekly to weekly, and then to every 2 weeks. Main Outcomes and Measures: The primary efficacy end point was change from baseline to day 8 (each period) in the Montgomery-Åsberg Depression Rating Scale (MADRS) total score. Results: Sixty-seven participants (38 women, mean [SD] age, 44.7 [10.0] years) were included in the efficacy and safety analyses. Change (least squares mean [SE] difference vs placebo) in MADRS total score (both periods combined) in all 3 esketamine groups was superior to placebo (esketamine 28 mg: -4.2 [2.09], P = .02; 56 mg: -6.3 [2.07], P = .001; 84 mg: -9.0 [2.13], P < .001), with a significant ascending dose-response relationship (P < .001). Improvement in depressive symptoms appeared to be sustained (-7.2 [1.84]) despite reduced dosing frequency in the open-label phase. Three of 56 (5%) esketamine-treated participants during the double-blind phase vs none receiving placebo and 1 of 57 participants (2%) during the open-label phase had adverse events that led to study discontinuation (1 event each of syncope, headache, dissociative syndrome, and ectopic pregnancy). Conclusions and Relevance: In this first clinical study to date of intranasal esketamine for TRD, antidepressant effect was rapid in onset and dose related. Response appeared to persist for more than 2 months with a lower dosing frequency. Results support further investigation in larger trials. Trial Registration: clinicaltrials.gov identifier: NCT01998958.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Moreover, formulations of ketamine are also being developed, and intranasal esketamine spray has shown high efficacy in treating MDD. 484”
From Major depressive disorder: hypothesis, mechanism, prevention and treatment (2024) · cites this paper as [484]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A breakthrough in the treatment of depression was the discovery that the anesthetic (R,S)-ketamine (ketamine), when administered at sub-anesthetic doses, elicits rapid (sometimes within hours) antidepressant effects in humans that are otherwise resistant to monoaminergic-acting therapies.”
From Mechanisms of ketamine and its metabolites as antidepressants (2022) · cites this paper as Daly et al., 2018
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This study observed a similar rapid reduction (within two hours) in depression symptoms as measured by the Montgomery-Åsberg Depression Rating Scale (MADRS) following an intranasal (S)-ketamine treatment (28 or 84 mg), which separated from placebo even at one week following a single administration.”
From Mechanisms of ketamine and its metabolites as antidepressants (2022) · cites this paper as Daly et al., 2018
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Unlike IV ketamine, there are also data demonstrating long- term (i.e., greater than 3- year) safety and tolerability for esketamine 194,195 .”
From Treatment‐resistant depression: definition, prevalence, detection, management, and investigational interventions (2023) · cites this paper as [194]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Intranasal esketamine spray co- initi ated with an antidepressant has also demonstrated rapid clinically meaningful efficacy in patients with TRD.”
From Treatment‐resistant depression: definition, prevalence, detection, management, and investigational interventions (2023) · cites this paper as [194]
Experimental — accuracy not yet measured
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Our findings are concordant with the direction and general magnitude of effect reported in pivotal trials of adjunctive intranasal esketamine in TRD and the relapse-prevention study (18–23)”
From Intranasal esketamine plus oral antidepressant for treatment-resistant depression: acute induction and maintenance relapse-prevention outcomes in a systematic review and meta-analysis (2026) · cites this paper as [18]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Results were consistent with previous findings from completed short-term (4-week) phase 2 and 3 studies.10,12,15”
From Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression: A Randomized Clinical Trial (2019) · cites this paper as [10]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Earlier studies of esketamine in patients with treatmentresistant depression (10,11) and major depression at imminent risk for suicide (12), which demonstrated greater magnitude of early response, applied a less stringent definition for response onset and employed site-based raters for efficacy evaluation.”
From Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study (2019) · cites this paper as [11]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Among these, six were initiation studies (1 with a 1-week duration [40], five with a 4-week duration [9–11, 41, 42] and one was a continuation study [12].”
The cited source says what the claim attributes to it.
In the citing paper
“We verified the positive efficacy at 1 week in NCT01998958 [40] but could not compare 4 out of 10 analyses due to unpublished results.”
The cited source says what the claim attributes to it.
In the citing paper
“The sample size planned for this study was calculated assuming a treatment difference for the double-blind treatment phase of 6.5 points in MADRS score between the esketamine plus antidepressant group and the antidepressant plus placebo group and a standard deviation of 12, based on the results of a phase 2 study of esketamine nasal spray for treatment-resistant depression (11) and clinical”
The cited source says what the claim attributes to it.
In the citing paper
“The magnitude of postdose blood pressure increases was lower compared with the previous phase 2 study of esketamine nasal spray (11), possibly because of the riskmitigation blood pressure guidelines initiated in phase 3 studies (see the online supplement).”
In the citing paper
“The approvals of esketamine nasal spray were based on efficacy and safety findings from phase 2/3 studies of TRD treatment for 4 weeks to 1 year [9–14].”
In the citing paper
“In addition, intranasal administration of 28–84 mg (S)-ketamine twice a week for a total period of two weeks induced antidepressant actions in treatment-resistant depressed patients as an adjunct treatment 119.”
From Mechanisms of ketamine action as an antidepressant (2018) · cites this paper as [119]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Brief Measure for Assessing Generalized Anxiety Disorder: The GAD-7
Spitzer, R. L., Kroenke, K., Williams, J. B. W., & Löwe, B. (2006) · Archives of Internal Medicine · doi:10.1001/archinte.166.10.1092 · Cited by 31,765
Diagnostic and Statistical Manual of Mental Disorders.
Widiger, T. A. (2000) · Oxford University Press eBooks · doi:10.1037/10518-009 · Cited by 19,766
A new depression scale designed to be sensitive to change
Montgomery, S. A., & Åsberg, M. (1979) · British Journal of Psychiatry · doi:10.1192/bjp.134.4.382 · Cited by 13,962
The Brief Psychiatric Rating Scale.
Overall, J. E., & Gorham, D. R. (1962) · Psychological Reports · doi:10.2466/pr0.1962.10.3.799 · Cited by 11,090
Cook, R. J., Dickens, B. M., & Fathalla, M. F. (2003) · Oxford University Press eBooks · doi:10.1093/acprof:oso/9780199241323.003.0025 · Cited by 10,825
(1976) · Medical Entomology and Zoology · Cited by 8,899
Vos, T., Barber, R. M., Bell, B., Bertozzi-Villa, A., Biryukov, S., Bolliger, I., Charlson, F., Davis, A., Degenhardt, L., Dicker, D., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)60692-4 · Cited by 6,414
Antidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856
Rush, A. J., Trivedi, M. H., Ibrahim, H. M., Carmody, T. J., Arnow, B., Klein, D. N., Markowitz, J. C., Ninan, P. T., Kornstein, S., Manber, R., et al. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(02)01866-8 · Cited by 3,829
Self-citation
Cited by
Sorted by citations
Items 401–500 of 714
Do antidepressants restore lost synapses?
Beyeler, A. (2019) · Science · doi:10.1126/science.aax0719 · Cited by 6
Richardson, L. G., & Brahmbhatt, A. (2020) · The Journal for Nurse Practitioners · doi:10.1016/j.nurpra.2020.09.002 · Cited by 10
Comments to Drs. Bahji, Vazquez, and Zarate
Drevets, W. C., Popova, V., Daly, E., Borentain, S., Lane, R., Cepeda, M. S., Mathews, M., Manji, H. K., & Canuso, C. M. (2021) · Journal of Affective Disorders · doi:10.1016/j.jad.2021.01.046 · Cited by 7
Self-citationNaudet, F., Pellen, C., Fodor, L. A., Gastaldon, C., Barbui, C., Turner, E. H., Le Pabic, E., & Cristea, I. A. (2025) · BMC Medicine · doi:10.1186/s12916-025-04435-x · Cited by 6
A real-world pharmacovigilance study of esketamine nasal spray
Chen, Y., Gu, H., Li, W., & Chen, Y. (2024) · Medicine · doi:10.1097/md.0000000000039484 · Cited by 6
Psychotic-Like Experiences in Young Recreational Users of Ketamine: A Case Study
Ricci, V., Berardis, D. D., Shoib, S., Martinotti, G., & Maina, G. (2025) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2025.2449909 · Cited by 6
Grasso, V., Tennyson, J., Airan, R. D., & Ianni, T. D. (2025) · Neuropsychopharmacology · doi:10.1038/s41386-025-02108-0 · Cited by 6
Pompili, M., Trocchia, M. A., Longhini, L., Dispenza, E., Legge, C. D., Sarubbi, S., Erbuto, D., & Berardelli, I. (2025) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.70008 · Cited by 7
Pisanu, C., Silva, R. C., Meattini, M., Gennarelli, M., Baune, B. T., Squassina, A., & Minelli, A. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.107894 · Cited by 8
Carmellini, P., Pinzi, M., Rescalli, M. B., & Cuomo, A. (2025) · Brain Sciences · doi:10.3390/brainsci16010018 · Cited by 7
Le, G. H., Wong, S., Johnson, D. E., Lu, A., Orsini, D. K., Chisamore, N., Luch, S. D. D., Rosenblat, J. D., & McIntyre, R. S. (2025) · Journal of Affective Disorders · doi:10.1016/j.jad.2025.121081 · Cited by 6
Shamabadi, A., Ahmadzade, A., Aqamolaei, A., Mortazavi, S. H., Hasanzadeh, A., & Akhondzadeh, S. (2022) · Iranian Journal of Psychiatry · doi:10.18502/ijps.v17i3.9733 · Cited by 9
Perspectives in treatment-resistant depression: esketamine and electroconvulsive therapy
Baldinger, P., Spies, M., Bozic, I., Kasper, S. F., Rujescu, D., & Frey, R. (2024) · Wiener klinische Wochenschrift · doi:10.1007/s00508-024-02358-w · Cited by 8
Juneja, K., Afroze, S., Goti, Z., Sahu, S., Asawa, S., Bhuchakra, H. P., Natarajan, B., & Pandey, S. (2024) · Discover Mental Health · doi:10.1007/s44192-024-00077-2 · Cited by 7
Novel treatments of depression: bridging the gap in current therapeutic approaches
Jagtiani, A. (2024) · Exploration of neuroscience · doi:10.37349/en.2024.00049 · Cited by 6
Xu, M., Wang, J., Shi, J., Wu, X., Zhao, Q., Shen, H., Chen, J., & Yu, J. (2025) · Neuropharmacology · doi:10.1016/j.neuropharm.2025.110362 · Cited by 8
Now is the time for (2R,6R)-hydroxynorketamine to be viewed independently from its parent drug
Chaki, S., & Yamaguchi, J. (2018) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2018.09.005 · Cited by 6
Ketamina, un nuevo agente terapéutico para la depresión
Pérez‐Esparza, R., Kobayashi-Romero, L. F., Mendoza, A. M. G., Lamas-Aguilar, R., Sosa, M. V., Encarnación-Martínez, M., González-Manríquez, L. A., Eternod-Rodríguez, S. A., Maltos-Gómez, F., Vargas-Valencia, K. M., et al. (2020) · Revista de la Facultad de Medicina UNAM · doi:10.22201/fm.24484865e.2020.63.1.02 · Cited by 9
The Unmet Needs for Major Depressive Disorder
McIntyre, R. S., & Gill, H. (2020) · Springer eBooks · doi:10.1007/978-3-030-42637-8_3 · Cited by 6
Fava, V. A. R., Sarin, L. M., Lucchese, A. C., Sant, L. C. D., Magalhães, E. T. P., Delfino, R. S., Tuena, M. A., Nakahira, C., Jackowski, A. P., Abdo, G. L., et al. (2020) · Revista de Psiquiatría y Salud Mental · doi:10.1016/j.rpsm.2020.10.003 · Cited by 6
Gallagher, B., Foley, M., Slattery, C. M., Gusciute, G., Shanahan, E., & McLoughlin, D. M. (2020) · HRB Open Research · doi:10.12688/hrbopenres.13182.1 · Cited by 7
Zhan, Z., Wang, X., Chen, Q., Xiao, Z., & Zhang, B. (2021) · BMJ Open · doi:10.1136/bmjopen-2020-043457 · Cited by 6
Zhou, Y., Ma, B., Sun, W., Wang, J., Fu, Y., Wang, A., Wang, G., & Han, R. (2022) · BMJ Open · doi:10.1136/bmjopen-2021-056713 · Cited by 7
Camargo, A., Dalmagro, A. P., Altê, G. A., Zeni, A. L. B., Tasca, C. I., & Rodrigues, A. L. S. (2023) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2023.110440 · Cited by 6
Arrighi, L., Maakaron, É., Korchia, T., Lançon, C., & Richieri, R. M. (2023) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000482 · Cited by 6
Oliveira-Maia, A., Rive, B., Morrens, J., Godinov, Y., Cabrieto, J., Perualila, N., & Mulhern-Haughey, S. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1250987 · Cited by 7
Efficacy and safety of zuranolone in the treatment of major depressive disorder: a meta-analysis
Wang, S., Zhang, W., Liu, Z., Zhang, T., Wang, Y., & Li, W. (2024) · Frontiers in Neuroscience · doi:10.3389/fnins.2023.1332329 · Cited by 6
Ma, B., Tao, X., Qi, Y., Cao, H., Cao, Q., Zhou, Z., & Wang, S. (2024) · Medicine · doi:10.1097/md.0000000000038821 · Cited by 6
Pochwat, B., Domin, H., Rafało-Ulińska, A., Szewczyk, B., & Nowak, G. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21134791 · Cited by 6
Intermittent repeated stress but not ketamine changes mice response to antidepressants
Borsoï, M., Nunes, L. E. D., Barbosa, A. R., Lima, M. S., Medeiros, I., Pranke, M. A., Antonio, C. B., Rates, S. M. K., & Neves, G. A. (2020) · Neuroscience Letters · doi:10.1016/j.neulet.2020.135452 · Cited by 6
Zheng, W., He, M., Gu, L.-M., Lao, G., Wang, D., Mai, J.-X., Wu, H., Nie, S., & Huang, X. (2022) · Journal of Affective Disorders · doi:10.1016/j.jad.2022.05.027 · Cited by 6
Vázquez, G. H., Gutiérrez, G., Rosenblat, J. D., Schaffer, A., Swainson, J., Ganapathy, K., Ravindran, N., Lam, R. W. M., Do, A., Giacobbe, P., et al. (2022) · BMJ Open · doi:10.1136/bmjopen-2022-060967 · Cited by 8
RAADs (Rapidly Acting Anti-depressants)—A quantum leap?
Naguy, A. (2019) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2019.07.048 · Cited by 6
The Treatment of Bipolar Depression: Current Status and Future Perspectives
Jelen, L. A., & Young, A. H. (2020) · Current Behavioral Neuroscience Reports · doi:10.1007/s40473-020-00200-x · Cited by 7
Li, J., Ma, L., Sun, H., Li, M., Cao, Y., Peng, Y., & Xu, J. (2025) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-024-01920-x · Cited by 5
Ammendolia, I., Mannucci, C., Esposito, E., Calapai, G., Currò, M., Midiri, P., Mondello, C., Cardia, L., & Calapai, F. (2025) · Pharmaceuticals · doi:10.3390/ph18050702 · Cited by 6
Liu, X., Liu, Y., Tu, J., Li, L., Long, T., Li, J., Deng, Y., Li, H., Peng, D., & Wu, G. (2025) · Neuroscience · doi:10.1016/j.neuroscience.2025.07.016 · Cited by 6
Li, M., Duan, W., Hao, X., Li, S., Wang, C., Liang, Y., Hu, Z., Ma, D., Guo, M., Zuo, C., et al. (2025) · Molecular Psychiatry · doi:10.1038/s41380-025-03198-4 · Cited by 5
Cavalcanti-Ribeiro, P., Souza, L. C. A. M. D., Tavares, V. D. D. O., de Almeida, R. N., Lima, N. B. D. M., Gonçalves, K. T. D. C., Lopes, E. I. T. C., Bolcont, R., de Brito, A. J. C., Falchi-Carvalho, M., et al. (2025) · Journal of Affective Disorders · doi:10.1016/j.jad.2025.120877 · Cited by 4
Zannikos, P., Solanki, B., Meulder, M. D., Badorrek, P., Hohlfeld, J. M., & Singh, J. B. (2023) · Clinical Pharmacokinetics · doi:10.1007/s40262-023-01273-z · Cited by 5
Self-citationAhmed, N. N., Albishi, F., Khan, S. A., Alsayegh, A., Stip, É., & Makhoul, S. (2023) · Middle East Current Psychiatry · doi:10.1186/s43045-023-00369-3 · Cited by 5
Research Progress on NMDA Receptor Enhancement Drugs for the Treatment of Depressive Disorder
Liu, R., Liu, N., Ma, L., Liu, Y., Huang, Z., Peng, X., Zhuang, C., Niu, J., Yu, J., & Du, J. (2024) · CNS Drugs · doi:10.1007/s40263-024-01123-x · Cited by 5
Mastrodonato, A., Jin, M., Kee, N., Lanio, M., Tapia, J., Quintana, L., Zamora, A., Deng, S., Xu, X., Landry, D. W., et al. (2024) · Biological Psychiatry · doi:10.1016/j.biopsych.2024.09.024 · Cited by 5
Nägele, P., Conway, C. R., & Zorumski, C. F. (2025) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2025.0900 · Cited by 5
Mario, A., Leccisotti, I., Claudia, M. M., Bellomo, A., Panza, F., Tommaso, C., & Madia, L. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118199 · Cited by 6
Barrutieta-Arberas, I., Ortuzar, N., Vaquero-Rodríguez, A., Picó-Gallardo, M., Bengoetxea, H., Guevara, M., Gargiulo, P. A., & Lafuente, J. V. (2023) · Experimental Biology and Medicine · doi:10.1177/15353702231170007 · Cited by 6
Intranasal ketamine as a treatment for psychiatric complications of long COVID: A case report
Baldwin, K., Wanson, A., Gilecki, L.-A., Dalton, C., Peters, E. M., & Halpape, K. (2023) · Mental Health Clinician · doi:10.9740/mhc.2023.10.239 · Cited by 5
Qiu, L., Chen, X., Fu, J., Chen, X., & Wang, X. (2024) · BMC Psychiatry · doi:10.1186/s12888-024-06035-0 · Cited by 9
Hong, X., Xu, S., Sun, G., Liu, Y., Yi, W., Hu, Q., Li, W., Liu, J., Wu, F., Yu, M., et al. (2025) · Journal of Affective Disorders · doi:10.1016/j.jad.2025.04.077 · Cited by 5
A commentary on: statistical inference problems in sequential parallel comparison designs
Schoenfeld, D., Doros, G. D., & D, M. F. M. (2019) · Journal of Biopharmaceutical Statistics · doi:10.1080/10543406.2019.1584207 · Cited by 5
The next psychoactive drugs: From imipramine to ketamine
Carrillo, P., Petit, A., Gaillard, R., & Vinckier, F. (2020) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/j.banm.2020.09.039 · Cited by 5
Clinical use of ketamine in psychiatric disorders
Dehestani, S., Mohammadpour, A. H., Sadjadi, S. A., Sathyapalan, T., & Sahebkar, A. (2022) · Annales Médico-psychologiques revue psychiatrique · doi:10.1016/j.amp.2022.05.008 · Cited by 6
Olivola, M., Arienti, V., Bassetti, N., Civardi, S. C., & Brondino, N. (2022) · EXCLI journal · doi:10.17179/excli2022-4694 · Cited by 5
Mansuri, Z., Shah, B., Yadav, G., Kamil, S. H., Kainth, T., Srinivas, S., Patel, H., Reddy, A., & Bachu, A. K. (2024) · The Primary Care Companion For CNS Disorders · doi:10.4088/pcc.23lr03607 · Cited by 5
Li, J., Jia, G., Wang, R., Zheng, R., & Yuan, K. (2025) · Drug Design Development and Therapy · doi:10.2147/dddt.s553693 · Cited by 4
Domżalska, M., Kwiatkowska, J., Cichoń, I., & Sokołowska, E. (2025) · Scientific Reports · doi:10.1038/s41598-025-29642-7 · Cited by 4
Research trends and hotspots of ketamine from 2014 to 2023: a bibliometric analysis
Wang, Y., Chang, S., & Chen, D. (2024) · Frontiers in Neuroscience · doi:10.3389/fnins.2024.1407301 · Cited by 6
Ketamine for refractory depression: Save the best for last?
Nigam, K. B., King, F., & Forcén, F. E. (2024) · Journal of Psychopharmacology · doi:10.1177/02698811241282646 · Cited by 4
Ansari, M., Rhee, T. G., Santucci, M. C., & Nikayin, S. (2025) · Journal of Affective Disorders · doi:10.1016/j.jad.2025.03.198 · Cited by 4
Massaneda‐Tuneu, C., Martin, D. M., Glozier, N., Bayes, A. J., Cao, T. V., Thornton, N. L. R., Brettell, L., Antoniou, S., Barreiros, A. R., Flynn, M., et al. (2025) · Journal of Affective Disorders · doi:10.1016/j.jad.2025.120192 · Cited by 4
Huang, C., Hu, L., Wu, L., Geng, F., Wong, G. T. C., Zhang, Y., Reif, A., Bao, Y., Xue, Q., & Lü, L. (2025) · Molecular Psychiatry · doi:10.1038/s41380-025-03320-6 · Cited by 11
Gillespie, C. F., Szabo, S. T., & Nemeroff, C. B. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-813866-3.00036-9 · Cited by 6
Cao, Y., Song, Y., Wang, Z., Tang, J., Yi, J., Liu, Y., An, L., Pan, Z., & Gao, H. Z. (2022) · Annals of Translational Medicine · doi:10.21037/atm-22-2614 · Cited by 4
La kétamine : un neuropsychotrope au mécanisme d’action innovant
Guilloux, J., Nguyen, T. M. L., & Gardier, A. M. (2023) · Biologie Aujourd hui · doi:10.1051/jbio/2023026 · Cited by 5
Self-Esteem, Resilience, And Mental Well-Being Among Students
Farooq, S., & Majeed, J. (2024) · doi:10.53555/kuey.v30i5.4647 · Cited by 13
Özcan, A. T. D., Akaycan, B., Can, S. S., Karakaya, Ö., Sönmez, E., Yastı, A. Ç., & Kanbak, O. (2024) · Journal of Burn Care & Research · doi:10.1093/jbcr/irae105 · Cited by 4
Fei, G., Yan, W. X., & Gan, Y. (2024) · Pakistan Journal of Medical Sciences · doi:10.12669/pjms.40.8.9883 · Cited by 4
Empowering understanding: navigating consent to ketamine treatment in adolescent mental health
Sathappan, A. V., & Yudkoff, B. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2024.1433348 · Cited by 4
Vieta, E., Arango, C., & Rush, A. J. (2018) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2018.07.104 · Cited by 4
Falkenberg, I., Bitsch, F., Liu, W., Matsingos, A., Noor, L., Vogelbacher, C., Yildiz, C., & Kircher, T. T. J. (2023) · Trials · doi:10.1186/s13063-023-07556-x · Cited by 4
Oliveira-Maia, A. J., Morrens, J., Rive, B., Godinov, Y., Cabrieto, J., Perualila, N. J., Barbreau, S., & Mulhern-Haughey, S. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1250980 · Cited by 4
Jha, M. K., & Trivedi, M. H. (2018) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.20180013 · Cited by 4
Lavretsky, H., & Roose, S. P. (2019) · American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2019.10.009 · Cited by 4
Editorial: Novel Approaches to the Treatment of Suicidality and Depression in Youth
Emslie, G. J. (2023) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2023.06.019 · Cited by 4
Ketamine treatment effects on DNA methylation and Epigenetic Biomarkers of agingPreprint
Dawson, K., Carangan, A. M. J. M., Klunder, J., Carreras-Gallo, N., Sehgal, R., Megilligan, S., Askins, B. C., Perkins, N., Mendez, T. L., Smith, R. C., et al. (2024) · medRxiv · doi:10.1101/2024.09.10.24313258 · Cited by 4
Neurobiological Foundations of Psychotherapies
Guina, J., Kay, J., & Yatim, F. (2024) · Springer eBooks · doi:10.1007/978-3-030-51366-5_168 · Cited by 3
Moleón-Ruiz, Á., de Toledo, P. Á., Pérez, I. G., Narbona, J., Gutiérrez-Rojas, L., & García, M. M.-B. (2025) · Psychiatry Research Case Reports · doi:10.1016/j.psycr.2025.100250 · Cited by 3
Ketamine for unipolar depression: A systematic review of efficacy and safety
Peiris, T. E., Pokhrel, A., & Paudel, Y. (2025) · Australasian Psychiatry · doi:10.1177/10398562251328805 · Cited by 3
Dodds, C., Dawson, R. L., Lim, A., Tye, S. J., & Nasrallah, F. A. (2025) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253251396255 · Cited by 4
Kaye, A. D., Wolf, M. C., Dufour, S. I., Haynes, A. T., Potharaju, P., Shekoohi, S., & Ahmadzadeh, S. (2025) · Current Pain and Headache Reports · doi:10.1007/s11916-025-01437-5 · Cited by 3
Hussein, Z. A., Taha, A. M., Abouelmagd, A. A., Elshabrawi, M. N., Durvesh, A. K., Nada, E., Abuelazm, M. T., Elnaggar, M., & Elkhattib, I. (2026) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-025-03935-2 · Cited by 3
Veraart, J. K. E., Smith-Apeldoorn, S. Y., Kamphuis, J., Touw, D. J., & Schoevers, R. A. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.177470 · Cited by 4
Genetics of Response to ECT , TMS , Ketamine and Esketamine
Franklin, C. E., Altinay, M. I., Bailey, K. J., Bhati, M. T., Carr, B. R., Conroy, S. K., Khurshid, K., McDonald, W. M., Mickey, B. J., Murrough, J. W., et al. (2025) · American Journal of Medical Genetics Part B Neuropsychiatric Genetics · doi:10.1002/ajmg.b.33038 · Cited by 3
Elmaadawi, A. Z., Naha, I., Prabhudesai, S., & Eltohami, M. (2025) · Psychiatry Research · doi:10.1016/j.psychres.2025.116821 · Cited by 3
Barnett, B. S. (2026) · Annals of Clinical Psychiatry · doi:10.1177/10401237261434394 · Cited by 4
Central sensitization and its role in chronic pain: What can ketamine do?
Singh, V., Shteamer, J. W., Lowe, J., & Callaway, M. A. (2020) · Indian Journal of Pain · doi:10.4103/ijpn.ijpn_25_20 · Cited by 3
Silberbauer, L., Bartova, L., Papageorgiou, K., Lanzenberger, R. R., Kasper, S. F., & Winkler, D. (2020) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001238 · Cited by 3
Kern, D. M., Cepeda, M. S., Flores, C. M., & Wittenberg, G. M. (2021) · CNS Drugs · doi:10.1007/s40263-020-00789-3 · Cited by 3
Consistency of the Antidepressant Effect of Intranasal Esketamine in Phase 3 Clinical Trials
Preskorn, S. (2021) · Journal of Psychiatric Practice · doi:10.1097/pra.0000000000000531 · Cited by 3
Sánchez‐Iglesias, I., & Martín-Aguilar, C. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12093181 · Cited by 3
Floriano, I., Silvinato, A., & Bernardo, W. M. (2023) · Revista da Associação Médica Brasileira · doi:10.1590/1806-9282.2023d696 · Cited by 9
Photocatalyzed Direct α‐Alkylation of Esters Using Styrenes
Wang, P., Bay, A. V., Farnam, E. J., & Scheidt, K. A. (2023) · Advanced Synthesis & Catalysis · doi:10.1002/adsc.202300253 · Cited by 3
Fei, G., Yan, W., & Yao, H. (2023) · Pakistan Journal of Medical Sciences · doi:10.12669/pjms.39.6.8057 · Cited by 3
Selinger, M. C., Compton, D. M., Morris, H., & Canty, T. J. (2023) · Journal of Behavioral and Brain Science · doi:10.4236/jbbs.2023.1312016 · Cited by 3
Licit use of illicit drugs for treating depression: the pill and the process
Pacheco, A. T., & Moghaddam, B. (2024) · Journal of Clinical Investigation · doi:10.1172/jci180217 · Cited by 3
Understanding the variability in ketamine’s efficacy in managing treatment-resistant depression
Bryan, J. (2024) · Discover Psychology · doi:10.1007/s44202-024-00277-5 · Cited by 3
Updates on Preclinical and Translational Neuroscience of Mood Disorders
Mischel, N., Kritzer, M. D., Patkar, A. A., Masand, P. S., & Szabo, S. T. (2019) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001132 · Cited by 3
Zheng, W., Sim, K., Ning, Y., & Xiang, Y. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.05.154 · Cited by 3
Regen, F., & Benkert, O. (2018) · Springer eBooks · doi:10.1007/978-3-662-57334-1_1 · Cited by 4
Ketamine for Treatment-Resistant Depression: A Gateway to Novel Treatment Approaches
Limandri, B. J. (2018) · Journal of Psychosocial Nursing and Mental Health Services · doi:10.3928/02793695-20180920-02 · Cited by 3
Metadata
- Authors
- Daly, E. J., Singh, J. B., Fedgchin, M., Cooper, K., Lim, P., Shelton, R. C., Thase, M. E., Winokur, A., Van Nueten, L., Manji, H., & Drevets, W. C.
- Affiliations
- Janssen Research & Development (United States) (US)
- Department of Neuroscience, Janssen Research & Development LLC, San Diego, California
- University of Alabama (US)
- University of Pennsylvania (US)
- UConn Health (US)
- Department of Neuroscience, Janssen Research & Development, Beerse, Belgium
- Corresponding author
- Daly, Ella J.
- ORCID
- Venue
- JAMA Psychiatry
- Publisher
- American Medical Association (AMA)
- Published
- 2018-02-01
- Volume
- 75
- Issue
- 2
- Pages
- 139
- ISSN
- 2168-622X (ISSN-L)
- PMC
- PMC5838571
- OpenAlex
- W2779386549
- Semantic Scholar
- b920d61a3ab10c4fbf2f123dd93cb19a9c3872f9
- Cited by
- 718
- References
- 51
- Citations by year
- 2026: 71 · 2025: 99 · 2024: 92 · 2023: 80 · 2022: 75 · 2021: 86 · 2020: 105 · 2019: 70 · 2018: 38
- FWCI
- 40.79
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- JAMA Psychiatry (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Keywords
- esketamine, treatment-resistant depression, major depressive disorder, intranasal administration, adjunctive therapy, antidepressant resistance, dose-response relationship, antidepressant efficacy, antidepressant safety, adverse events, NMDA receptor antagonists, ketamine derivatives, open-label extension, relapse prevention, treatment-emergent adverse events
- MeSH terms
- Administration, Intranasal, Administration, Oral, Adult, Antidepressive Agents, Major Depressive Disorder, Dose-Response Relationship, Drug, Double-Blind Method, Drug Administration Schedule, Drug Therapy, Combination, Female, Follow-Up Studies, Humans, Ketamine, Male, Middle Aged, Treatment Outcome, Young Adult, Depressive Disorder, Treatment-Resistant
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
